Skip to main content

23-10-2020 | Oncology | News | Article


FDA recommends nivolumab–ipilimumab for inoperable mesothelioma

Lynda Williams

medwireNews: The US FDA has approved nivolumab plus ipilimumab as a first-line treatment for unresectable malignant pleural mesothelioma.

The decision follows the CheckMate 743 trial results showing a significant improvement in overall survival with the combination compared with cisplatin or carboplatin plus pemetrexed chemotherapy.

The recommended dosage is nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks for up to 2 years or until disease progression or unacceptable toxicity.

The most common adverse events reported by trial participants include fatigue, musculoskeletal pain, rash, dyspnea, gastrointestinal symptoms, cough, and pruritus.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage